AIM Vaccine (HKG:6660) said China's National Medical Products Administration (NMPA) approved clinical trials for its tetanus vaccine, according to a Thursday filing with the Hong Kong bourse.
The company is actively promoting the research and development of diphtheria, tetanus, and acellular pertussis HIB combined vaccine, the Tetravaccine, the filing added.
The company's share prices were up nearly 5% in recent trading.